Interim methods for development of inhalation reference concentrations. Draft report
Technical Report
·
OSTI ID:6409660
An inhalation reference concentration (RfC) is an estimate of continuous inhalation exposure over a human lifetime that is unlikely to pose significant risk of adverse noncancer health effects and serves as a benchmark value for assisting in risk management decisions. Derivation of an RfC involves dose-response assessment of animal data to determine the exposure levels at which no significant increase in the frequency or severity of adverse effects between the exposed population and its appropriate control exists. The assessment requires an interspecies dose extrapolation from a no-observed-adverse-effect level (NOAEL) exposure concentration of an animal to a human equivalent NOAEL (NOAEL(HBC)). The RfC is derived from the NOAEL(HBC) by the application of generally order-of-magnitude uncertainty factors. Intermittent exposure scenarios in animals are extrapolated to chronic continuous human exposures. Relationships between external exposures and internal doses depend upon complex simultaneous and consecutive processes of absorption, distribution, metabolism, storage, detoxification, and elimination. To estimate NOAEL(HBC)s when chemical-specific physiologically-based pharmacokinetic models are not available, a dosimetric extrapolation procedure based on anatomical and physiological parameters of the exposed human and animal and the physical parameters of the toxic chemical has been developed which gives equivalent or more conservative exposure concentrations values than those that would be obtained with a PB-PK model.
- Research Organization:
- Environmental Protection Agency, Research Triangle Park, NC (USA). Environmental Criteria and Assessment Office
- OSTI ID:
- 6409660
- Report Number(s):
- PB-90-238890/XAB; EPA--600/8-90/066A
- Country of Publication:
- United States
- Language:
- English
Similar Records
Estimating human-equivalent no observed adverse-effect levels for VOCs (volatile organic compounds) based on minimal knowledge of physiological parameters. Technical paper
Incorporation of pharmacokinetics in noncancer risk assessment: Example with chloropentafluorobenzene
Using physiologically based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Technical Report
·
Sat Dec 31 23:00:00 EST 1988
·
OSTI ID:5599016
Incorporation of pharmacokinetics in noncancer risk assessment: Example with chloropentafluorobenzene
Conference
·
Wed Jun 01 00:00:00 EDT 1994
· Risk Analysis; (United States)
·
OSTI ID:7008362
Using physiologically based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate.
Journal Article
·
Thu Mar 31 23:00:00 EST 2005
· Risk Analysis
·
OSTI ID:15016802
Related Subjects
560300* -- Chemicals Metabolism & Toxicology
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMALS
BIOLOGICAL MODELS
CHRONIC EXPOSURE
DOSE-RESPONSE RELATIONSHIPS
INHALATION
INTAKE
LABORATORY ANIMALS
MAMMALS
MAN
METABOLISM
PRIMATES
RISK ASSESSMENT
TOXICITY
VERTEBRATES
XENOBIOTICS
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANIMALS
BIOLOGICAL MODELS
CHRONIC EXPOSURE
DOSE-RESPONSE RELATIONSHIPS
INHALATION
INTAKE
LABORATORY ANIMALS
MAMMALS
MAN
METABOLISM
PRIMATES
RISK ASSESSMENT
TOXICITY
VERTEBRATES
XENOBIOTICS